1 TLB PowerPoint presented By Takaya L. Brown, BSN, BSN, CMSRN.

Slides:



Advertisements
Similar presentations
Unstable angina and NSTEMI
Advertisements

Peripheral vessel: mechanical or chemical closure
CARE OF THE CARDIAC CATH PATIENT Meg Morris, RN, CCRN, Nurse Clinician II Zir Cardiac Cath Lab January 20, 2011.
Drugs for Coagulation Disorders
Vascular Closure Devices. What is a Closure Device Vascular closure devices seal the puncture site in an artery (the arteriotomy) through mechanical means.
IRTB - Arterial Access and Angioplasty Dr Hilary White Nottingham.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Access Site Complications Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary’s Hospital Campus.
Percutaneous Insertion Use and Contraindications.
Molina Allen This presentation was prepared for COHP 450, Section VL1, taught by Dr. Njoku.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
PCI Percutaneous Coronary Intervention prepared by: Sue Feltham RN, ACNP revised by: Amanda Darwood RN, BSc.
Antiplatelet Drugs - Principles Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
USE OF CITRATED CLOTTING TIME IN MONITORING ENOXAPARIN LEVEL DURING CONTEMPORARY PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROMES B.Y.C.
“Access Anxiety” John F Eidt MD Ahsan Ali MD Mohammed Moursi MD University of Arkansas for Medical Sciences.
Applications of bivalirudin in interventional cardiology
TUESDAY 19TH OCTOBER2010 CATH LAB PRESENTATION. TAO /ACS study STUDY NUMBER: EFC6204 Randomized, double-blind, triple-dummy trial to compare the efficacy.
Use of Arteriotomy Closure Devices and the Risk of Vascular Complications: An Analysis of 227,879 Patients in the NCDR Sameer K. Mehta MD, Andrew D. Frutkin.
ANTIPLATELET DRUGS.
Developed by: Dawn Johnson, RN, MSN, Ed.  Internally and externally  Prevent bleeding from wounds which could lead to shock or even death.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
PCI What You Need to Know!. What and Where Radial- advantages  Immediate ambulation  Easily compressible vessel  Less risk of nerve injury  Dual blood.
Arterial access פרופ ' אריאל רוגין מנהל היחידה לקרדיולוגיה פולשנית מרכז רפואי רמב " ם, חיפה.
ATH: A Novel Heparin-Based Anticoagulant
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.
ANTIPLATELETES AGENTS
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Agents Affecting Blood Clotting
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.
Prof. Abdulrahman Almotrefi
Zoltan G. Turi, M.D. Cooper University Hospital Cooper Medical School of Rowan University Camden, NJ Vascular Access and Closure.
Support for implementing NICE guidance: Unstable angina and NSTEMI Unstable angina and NSTEMI, CG94, rd Edition March 2014.
Impact of Anticoagulation Regimens on Sheath Management and Bleeding in Patients Undergoing Elective Percutaneous Coronary Intervention in the STEEPLE.
Material and Methods Patient Population. – From July 2005 through December 2008, 130 patients (130 procedures, 154 limbs, 185 lesions) were treated using.
IV Therapy Vema Sweitzer, MN,RN.
Zoltan G. Turi, M.D. Professor of Medicine University of Medicine and Dentistry of New Jersey A Bad Vascular Access and Closure Outcome.
II. Antiplatelet Drugs.
23 Anticoagulants.
Transfemoral Access Devices & Tips for Closures Devices
University Emergency Hospital «Pirogov» Sofia
Management of ST-Elevation Myocardial Infarction
Women, Bleeding, and Coronary Intervention
Ischaemic Heart Disease Acute Coronary Syndrome
Groin Complication from Access Closure Failures
Cardiac Cath NUR 422.
Vascular Access and Vascular Closure Devices
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Glenn N. Levine et al. JACC 2016;68:
Chapter 28 Management of Patients With Coronary Vascular Disorders
Mandeep Singh, MD, MPH, Deepak L. Bhatt, MD, MPH, Gregg W
The following slides highlight a Hotline presentation at the European Society of Cardiology Congress in Barcelona, Spain, August 29 – September 2, 2009.
Section F: Clinical guidelines
Gregg W. Stone, MD, Herbert D. Aronow, MD, MPH  Mayo Clinic Proceedings 
% Heparin + GPI IIb/IIIa Bivalirudin +
Impact of Platelet Reactivity Following Clopidogrel Administration
23 Anticoagulants.
C-2. Clinical trial updates: Direct thrombin inhibitors
Percutaneous arterial closure in peripheral vascular disease: a prospective randomized evaluation of the Perclose device  B.W Starnes, MD, S.D O’Donnell,
Nat. Rev. Cardiol. doi: /nrcardio
Prof. Abdulrahman Almotrefi
Increase interdisciplinary communication
Section B: Science update
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Presentation transcript:

1 TLB PowerPoint presented By Takaya L. Brown, BSN, BSN, CMSRN

Percutaneous Coronary Intervention : a nonsurgical procedure that is done to open narrowed coronary arteries; performed by introducing a catheter through the skin into an artery (groin or arm). This procedure is performed when a patient has an acute coronary syndrome or a non-ST elevation MI. PCI reduces morbidity and mortality from cardiovascular disease. icle_em.htm 2 TLB

Because PCI requires the use of potent antithrombotic agents/Antithrombin medications, there is an increased risk of: Hematoma Retroperitoneal hematoma Pseudoaneurysm Arterial occlusion Arteriovenous fistula Increased morbidity/mortality Increased costs FVACs reported during PCI are %. Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5): TLB

Modifiable  Procedural technique  Medications  Hemostasis method Non-modifiable  Sex  Age  BMI  Blood pressure Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5): Since nurses are generally the ones to pull the catheters or sheaths, it is important to understand causes and predisposing risk factors of VASCs. 4 TLB

Many VASCs are related to punctures being made either too high or too low below the inguinal ligament. Low sticks can lead to pseudoaneurysm, hematoma, or AV fistula. Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5): TLB

Table 1 Femoral puncture location and associated complications a Femoral puncture location: definition Low stick: puncture below the femoral bifurcation High stick: puncturing the inferior epigastric artery Posterior wall puncture: puncture through the back wall of the artery Complications Pseudoaneurysm Hematoma Arteriovenous fistula Retroperitoneal hemorrhage a Based on data from Turi,7 Ragosta,8 Baim and Simon,15 Kamineni and Butman,18 and Rashid and Bailey Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5): TLB

Combinations of oral, IV antiplatelet, and antithrombin therapy are used for patients with ACS (USA and non-STEMI).  They reduce mortality rates  They reduce adverse ischemic events, such as recurrent MI  They reduce short and long term complications of PCI AntithrombinAntiplatelets Inhibits the coagulation factors that act in the clotting cascade to form fibrin strands 1.Unfractionated heparin (UFH) 2.Low molecular weight heparin (LMWH): little effect on measurements of activated clotting time 3.Direct thrombin inhibitors (bivalrudin, argatroban): interact directly with thrombin without the need for cofactor Prevent formation of clots by allowing platelets to be activated 1.Glycoprotein Iib/IIIa (reopro, integrilin, aggrastat) 2.Adenosine diphosphate inhibitors (plavix, prasugrel) 3.aspirin Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5): TLB

8 These organizations support early administration of glycoprotein IIB/IIIa inhibitors for patients at high risk for thrombotic events related to bleeding. Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5):

There are three main techniques for obtaining hemostasis: 1. Manual compression 2. Mechanical compression 3. Vascular closure devices Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5): TLB

This is the gold standard for pulling sheaths and obtaining hemostasis. Place index and middle fingers 1-2cm above puncture site and apply pressure for minutes. This can lead to VASCs due to varying amounts of pressure being applied as a result of hand and arm fatigue. 10 TLB Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5):

TLB 11 Applying constant pressure on the artery by use of: C-clamp Pneumatic device(Fem-stop) Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5):

TLB 12 This method was first approved in the 1990’s as a means for reducing length of bedrest, improving hemostasis, and for patient’s comfort. Methods used: -sutures for tying of the femoral artery -collagenlike plugs which seals the puncture site by stimulating platelet aggregation -staples/clips which seal off puncture site in the artery starclose angioseal perclose Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5):

Critically ill patients are at high risk for VASCs because of comorbid conditions, such as, -renal failure -hypertension -advanced age The goal for nursing is to maintain hemostasis at the puncture site. This goal will be attained by frequent assessment of VASCs: -frequent vital sign checks -frequent puncture site checks for bleeding or hematoma -frequent pulse checks of affected limb TLB 13 Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5):

TLB 14 Merriweather, N. & Sulzbach-Hoke, L. (2012). Managing risk of complications at femoral vascular access sites in PCI. Critical care nurse, 32(5):

TLB 15 Article can be found on the AACN (C1253) website. After completing the test, you will receive 1.0 contact hours. 3.pdf